Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
32
IOVA Quote, Financials, Valuation and Earnings
Last price:
$2.52
Seasonality move
:
3.53%
Day range:
$2.69 - $2.83
52-week range:
$1.64 - $7.97
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.34x
P/B ratio:
1.42x
Volume:
15.1M
Avg. volume:
11M
1-year change:
-67.65%
Market cap:
$1B
Revenue:
$164.1M
EPS (TTM):
-$1.20
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IOVA
Iovance Biotherapeutics, Inc.
|
$82.8M | -$0.15 | 11.5% | -35.2% | $8.35 |
|
CATX
Perspective Therapeutics, Inc.
|
$211.4K | -$0.35 | -9.65% | -37.91% | $12.3077 |
|
ELMD
Electromed, Inc.
|
$17.8M | -- | 11.04% | -- | $36.00 |
|
INFU
InfuSystem Holdings, Inc.
|
$34.6M | $0.05 | 8.36% | 39.86% | $14.20 |
|
NTLA
Intellia Therapeutics, Inc.
|
$10.4M | -$0.99 | -5.45% | -23.69% | $22.43 |
|
PSTV
Plus Therapeutics, Inc.
|
$1.4M | -$0.04 | -1.06% | -93.96% | $7.16 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IOVA
Iovance Biotherapeutics, Inc.
|
$2.52 | $8.35 | $1B | -- | $0.00 | 0% | 3.34x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.7900 | $12.3077 | $207.4M | -- | $0.00 | 0% | 189.17x |
|
ELMD
Electromed, Inc.
|
$27.39 | $36.00 | $228.4M | 29.47x | $0.00 | 0% | 3.65x |
|
INFU
InfuSystem Holdings, Inc.
|
$8.39 | $14.20 | $170.6M | 32.08x | $0.00 | 0% | 1.26x |
|
NTLA
Intellia Therapeutics, Inc.
|
$9.21 | $22.43 | $1.1B | -- | $0.00 | 0% | 16.78x |
|
PSTV
Plus Therapeutics, Inc.
|
$0.56 | $7.16 | $76.3M | -- | $0.00 | 0% | 8.89x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IOVA
Iovance Biotherapeutics, Inc.
|
6.96% | -0.909 | 6.28% | 2.92x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.042 | 1.3% | 8.47x |
|
ELMD
Electromed, Inc.
|
-- | 1.105 | -- | 4.58x |
|
INFU
InfuSystem Holdings, Inc.
|
30.8% | 4.042 | 11.73% | 1.35x |
|
NTLA
Intellia Therapeutics, Inc.
|
11.58% | 2.838 | 4.9% | 5.57x |
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -1.184 | 0.02% | 1.22x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IOVA
Iovance Biotherapeutics, Inc.
|
$20M | -$89.8M | -50.35% | -54.43% | -133.06% | -$89.5M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
ELMD
Electromed, Inc.
|
$13.2M | $2.7M | 18.88% | 18.89% | 15.81% | -$98K |
|
INFU
InfuSystem Holdings, Inc.
|
$20.3M | $3.8M | 6.43% | 9.93% | 10.45% | $8.4M |
|
NTLA
Intellia Therapeutics, Inc.
|
$8.8M | -$111.5M | -47.33% | -54.66% | -808.86% | -$76.9M |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
Iovance Biotherapeutics, Inc. vs. Competitors
-
Which has Higher Returns IOVA or CATX?
Perspective Therapeutics, Inc. has a net margin of -135.28% compared to Iovance Biotherapeutics, Inc.'s net margin of -12425.36%. Iovance Biotherapeutics, Inc.'s return on equity of -54.43% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital IOVAIovance Biotherapeutics, Inc.29.61% -$0.25 $754.8M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About IOVA or CATX?
Iovance Biotherapeutics, Inc. has a consensus price target of $8.35, signalling upside risk potential of 231.35%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 341.14%. Given that Perspective Therapeutics, Inc. has higher upside potential than Iovance Biotherapeutics, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Iovance Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IOVAIovance Biotherapeutics, Inc.6 4 1 CATXPerspective Therapeutics, Inc.12 1 0 -
Is IOVA or CATX More Risky?
Iovance Biotherapeutics, Inc. has a beta of 0.771, which suggesting that the stock is 22.905% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.
-
Which is a Better Dividend Stock IOVA or CATX?
Iovance Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iovance Biotherapeutics, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IOVA or CATX?
Iovance Biotherapeutics, Inc. quarterly revenues are $67.5M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Iovance Biotherapeutics, Inc.'s net income of -$91.3M is lower than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Iovance Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics, Inc. is 3.34x versus 189.17x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IOVAIovance Biotherapeutics, Inc.3.34x -- $67.5M -$91.3M CATXPerspective Therapeutics, Inc.189.17x -- $209K -$26M
-
Which has Higher Returns IOVA or ELMD?
Electromed, Inc. has a net margin of -135.28% compared to Iovance Biotherapeutics, Inc.'s net margin of 12.65%. Iovance Biotherapeutics, Inc.'s return on equity of -54.43% beat Electromed, Inc.'s return on equity of 18.89%.
Company Gross Margin Earnings Per Share Invested Capital IOVAIovance Biotherapeutics, Inc.29.61% -$0.25 $754.8M ELMDElectromed, Inc.78.15% $0.25 $44.7M -
What do Analysts Say About IOVA or ELMD?
Iovance Biotherapeutics, Inc. has a consensus price target of $8.35, signalling upside risk potential of 231.35%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 31.44%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Electromed, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Electromed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IOVAIovance Biotherapeutics, Inc.6 4 1 ELMDElectromed, Inc.4 0 0 -
Is IOVA or ELMD More Risky?
Iovance Biotherapeutics, Inc. has a beta of 0.771, which suggesting that the stock is 22.905% less volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.266, suggesting its less volatile than the S&P 500 by 73.442%.
-
Which is a Better Dividend Stock IOVA or ELMD?
Iovance Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iovance Biotherapeutics, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IOVA or ELMD?
Iovance Biotherapeutics, Inc. quarterly revenues are $67.5M, which are larger than Electromed, Inc. quarterly revenues of $16.9M. Iovance Biotherapeutics, Inc.'s net income of -$91.3M is lower than Electromed, Inc.'s net income of $2.1M. Notably, Iovance Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 29.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics, Inc. is 3.34x versus 3.65x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IOVAIovance Biotherapeutics, Inc.3.34x -- $67.5M -$91.3M ELMDElectromed, Inc.3.65x 29.47x $16.9M $2.1M
-
Which has Higher Returns IOVA or INFU?
InfuSystem Holdings, Inc. has a net margin of -135.28% compared to Iovance Biotherapeutics, Inc.'s net margin of 6.19%. Iovance Biotherapeutics, Inc.'s return on equity of -54.43% beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.
Company Gross Margin Earnings Per Share Invested Capital IOVAIovance Biotherapeutics, Inc.29.61% -$0.25 $754.8M INFUInfuSystem Holdings, Inc.55.65% $0.11 $80.2M -
What do Analysts Say About IOVA or INFU?
Iovance Biotherapeutics, Inc. has a consensus price target of $8.35, signalling upside risk potential of 231.35%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 69.25%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than InfuSystem Holdings, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than InfuSystem Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IOVAIovance Biotherapeutics, Inc.6 4 1 INFUInfuSystem Holdings, Inc.5 0 0 -
Is IOVA or INFU More Risky?
Iovance Biotherapeutics, Inc. has a beta of 0.771, which suggesting that the stock is 22.905% less volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.680, suggesting its more volatile than the S&P 500 by 68.01%.
-
Which is a Better Dividend Stock IOVA or INFU?
Iovance Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iovance Biotherapeutics, Inc. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IOVA or INFU?
Iovance Biotherapeutics, Inc. quarterly revenues are $67.5M, which are larger than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. Iovance Biotherapeutics, Inc.'s net income of -$91.3M is lower than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, Iovance Biotherapeutics, Inc.'s price-to-earnings ratio is -- while InfuSystem Holdings, Inc.'s PE ratio is 32.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics, Inc. is 3.34x versus 1.26x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IOVAIovance Biotherapeutics, Inc.3.34x -- $67.5M -$91.3M INFUInfuSystem Holdings, Inc.1.26x 32.08x $36.5M $2.3M
-
Which has Higher Returns IOVA or NTLA?
Intellia Therapeutics, Inc. has a net margin of -135.28% compared to Iovance Biotherapeutics, Inc.'s net margin of -735.19%. Iovance Biotherapeutics, Inc.'s return on equity of -54.43% beat Intellia Therapeutics, Inc.'s return on equity of -54.66%.
Company Gross Margin Earnings Per Share Invested Capital IOVAIovance Biotherapeutics, Inc.29.61% -$0.25 $754.8M NTLAIntellia Therapeutics, Inc.64.19% -$0.92 $846.4M -
What do Analysts Say About IOVA or NTLA?
Iovance Biotherapeutics, Inc. has a consensus price target of $8.35, signalling upside risk potential of 231.35%. On the other hand Intellia Therapeutics, Inc. has an analysts' consensus of $22.43 which suggests that it could grow by 143.56%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Intellia Therapeutics, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Intellia Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IOVAIovance Biotherapeutics, Inc.6 4 1 NTLAIntellia Therapeutics, Inc.10 11 1 -
Is IOVA or NTLA More Risky?
Iovance Biotherapeutics, Inc. has a beta of 0.771, which suggesting that the stock is 22.905% less volatile than S&P 500. In comparison Intellia Therapeutics, Inc. has a beta of 2.054, suggesting its more volatile than the S&P 500 by 105.378%.
-
Which is a Better Dividend Stock IOVA or NTLA?
Iovance Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iovance Biotherapeutics, Inc. pays -- of its earnings as a dividend. Intellia Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IOVA or NTLA?
Iovance Biotherapeutics, Inc. quarterly revenues are $67.5M, which are larger than Intellia Therapeutics, Inc. quarterly revenues of $13.8M. Iovance Biotherapeutics, Inc.'s net income of -$91.3M is higher than Intellia Therapeutics, Inc.'s net income of -$101.3M. Notably, Iovance Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Intellia Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics, Inc. is 3.34x versus 16.78x for Intellia Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IOVAIovance Biotherapeutics, Inc.3.34x -- $67.5M -$91.3M NTLAIntellia Therapeutics, Inc.16.78x -- $13.8M -$101.3M
-
Which has Higher Returns IOVA or PSTV?
Plus Therapeutics, Inc. has a net margin of -135.28% compared to Iovance Biotherapeutics, Inc.'s net margin of -316.61%. Iovance Biotherapeutics, Inc.'s return on equity of -54.43% beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IOVAIovance Biotherapeutics, Inc.29.61% -$0.25 $754.8M PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M -
What do Analysts Say About IOVA or PSTV?
Iovance Biotherapeutics, Inc. has a consensus price target of $8.35, signalling upside risk potential of 231.35%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $7.16 which suggests that it could grow by 1189.64%. Given that Plus Therapeutics, Inc. has higher upside potential than Iovance Biotherapeutics, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Iovance Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IOVAIovance Biotherapeutics, Inc.6 4 1 PSTVPlus Therapeutics, Inc.3 0 0 -
Is IOVA or PSTV More Risky?
Iovance Biotherapeutics, Inc. has a beta of 0.771, which suggesting that the stock is 22.905% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.845, suggesting its less volatile than the S&P 500 by 15.456%.
-
Which is a Better Dividend Stock IOVA or PSTV?
Iovance Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iovance Biotherapeutics, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IOVA or PSTV?
Iovance Biotherapeutics, Inc. quarterly revenues are $67.5M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Iovance Biotherapeutics, Inc.'s net income of -$91.3M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Iovance Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics, Inc. is 3.34x versus 8.89x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IOVAIovance Biotherapeutics, Inc.3.34x -- $67.5M -$91.3M PSTVPlus Therapeutics, Inc.8.89x -- $1.4M -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
55
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
45
CTEV alert for Jan 4
Claritev Corp. [CTEV] is down 20.7% over the past day.
Buy
60
BIDU alert for Jan 3
Baidu, Inc. [BIDU] is up 15.01% over the past day.
Sell
47
ASTS alert for Jan 4
AST Spacemobile, Inc. [ASTS] is up 14.94% over the past day.
